← Back to Search

Resilience-Building Intervention for Aging Individuals with HIV (RISE+ Trial)

N/A

Waitlist Available

Research Sponsored by University of Alabama at Birmingham

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have a recent history (within the past 12 months) of suboptimal HIV management, defined as having either ≥one record of detectable viral load or ≥one missed clinic visit without prior cancellation/reschedule

Age 50+

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months after intervention

Awards & highlights

RISE+ Trial Summary

This trial tests how a resilience-building program helps older people living with HIV to cope and improve their quality of life.

Who is the study for?

This trial is for people over 50 with HIV who are patients at the UAB HIV Clinic. They should have had some trouble managing their HIV in the last year, like missing a clinic visit or having a detectable viral load. People with serious mental health conditions like schizophrenia, bipolar disorder, or major depression cannot join.Check my eligibility

What is being tested?

The study is testing RISE+, an intervention designed to help build resilience and reduce stress in older adults living with HIV. It will be compared to a control group that receives standard stress reduction guidance.See study design

What are the potential side effects?

Since this trial focuses on psychological interventions rather than medications, traditional side effects are not expected. However, participants may experience emotional discomfort when discussing personal topics during sessions.

RISE+ Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My HIV has not been well-managed in the past year, with missed appointments or detectable viral loads.

Select...

I am 50 years old or older.

RISE+ Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months after intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months after intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

resilience resources

stress reactivity

Secondary outcome measures

HIV Treatment Management Abilities

HIV Viral Load

HIV medication adherence

+2 more

RISE+ Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: RISE+ Resilience InterventionExperimental Treatment1 Intervention

Participants in the intervention group will come to the lab for four two-hour weekly sessions in small groups of 3-4. The intervention includes psychoeducational videos and individual written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience. The intervention will be facilitated by a trained research assistant but as in the pilot study, he/she will be minimally involved (i.e., only administering the videos and explaining the activities) to keep the private reflective nature of the program that participants liked. Upon completion of the program, participants will be given handouts with summaries of the program material. We will gather qualitative and quantitative feedback on the intervention at the one-month posttest.

Group II: Stress Reduction ControlPlacebo Group1 Intervention

Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games. As with the intervention group, participants in the control group will come to the lab for four two-hour weekly sessions in small groups of 3-4. Facilitator involvement will be the same as the intervention group (e.g., the research assistant will explain computer activities and games but will otherwise not interact with the participant).

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor

1,583 Previous Clinical Trials

2,279,944 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,669 Previous Clinical Trials

28,005,014 Total Patients Enrolled

Media Library

RISE+ Clinical Trial Eligibility Overview. Trial Name: NCT05314088 — N/A

HIV Research Study Groups: Stress Reduction Control, RISE+ Resilience Intervention

HIV Clinical Trial 2023: RISE+ Highlights & Side Effects. Trial Name: NCT05314088 — N/A

RISE+ 2023 Treatment Timeline for Medical Study. Trial Name: NCT05314088 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any new participants being accepted for this experiment at the moment?

"According to information on clinicaltrials.gov, this medical investigation is not currently enrolling patients. The study was initially posted on February 3rd 2023 and its last update occurred 5 days later. Although the trial isn't actively recruiting right now, 207 other trials are open for participation presently."

Answered by AI

What objectives do researchers hope to accomplish with this investigation?

"At the conclusion of the four-week intervention period, stress reactivity is primary measure that will be assessed. Additionally, depressive symptoms (using Centers for Epidemiological Studies Depression Scale), HIV Viral Load (copies per mL of plasma from medical records) and HIV medication adherence (Visual Analogue Scale ART adherence) are secondary objectives to be evaluated."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV

Pariya L. Fazeli, PhD 2023. "Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05314088.